Literature DB >> 18757400

BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.

Kimberly Cramer1, Margaret Nieborowska-Skorska, Mateusz Koptyra, Artur Slupianek, Emir Tyrone P Penserga, Connie J Eaves, Walter Aulitzky, Tomasz Skorski.   

Abstract

Myeloproliferative disorders (MPD) are stem cell-derived clonal diseases arising as a consequence of acquired aberrations in c-ABL, Janus-activated kinase 2 (JAK2), and platelet-derived growth factor receptor (PDGFR) that generate oncogenic fusion tyrosine kinases (FTK), including BCR/ABL, TEL/ABL, TEL/JAK2, and TEL/PDGFbetaR. Here, we show that FTKs stimulate the formation of reactive oxygen species and DNA double-strand breaks (DSB) both in hematopoietic cell lines and in CD34(+) leukemic stem/progenitor cells from patients with chronic myelogenous leukemia (CML). Single-strand annealing (SSA) represents a relatively rare but very unfaithful DSB repair mechanism causing chromosomal aberrations. Using a specific reporter cassette integrated into genomic DNA, we found that BCR/ABL and other FTKs stimulated SSA activity. Imatinib-mediated inhibition of BCR/ABL abrogated this effect, implicating a kinase-dependent mechanism. Y253F, E255K, T315I, and H396P mutants of BCR/ABL that confer imatinib resistance also stimulated SSA. Increased expression of either nonmutated or mutated BCR/ABL kinase, as is typical of blast phase cells and very primitive chronic phase CML cells, was associated with higher SSA activity. BCR/ABL-mediated stimulation of SSA was accompanied by enhanced nuclear colocalization of RAD52 and ERCC1, which play a key role in the repair. Taken together, these findings suggest a role of FTKs in causing disease progression in MPDs by inducing chromosomal instability through the production of DSBs and stimulation of SSA repair.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757400      PMCID: PMC2531069          DOI: 10.1158/0008-5472.CAN-08-1101

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52.

Authors:  Teresa A Motycka; Tadayoshi Bessho; Sean M Post; Patrick Sung; Alan E Tomkinson
Journal:  J Biol Chem       Date:  2004-01-20       Impact factor: 5.157

2.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Authors:  Paolo Neviani; Ramasamy Santhanam; Rossana Trotta; Mario Notari; Bradley W Blaser; Shujun Liu; Hsiaoyin Mao; Ji Suk Chang; Annamaria Galietta; Ashwin Uttam; Denis C Roy; Mauro Valtieri; Rebecca Bruner-Klisovic; Michael A Caligiuri; Clara D Bloomfield; Guido Marcucci; Danilo Perrotti
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

3.  Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

Authors:  Ian J Griswold; Mary MacPartlin; Thomas Bumm; Valerie L Goss; Thomas O'Hare; Kimberly A Lee; Amie S Corbin; Eric P Stoffregen; Caitlyn Smith; Kara Johnson; Erika M Moseson; Lisa J Wood; Roberto D Polakiewicz; Brian J Druker; Michael W Deininger
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

4.  BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.

Authors:  Artur Slupianek; Michal O Nowicki; Mateusz Koptyra; Tomasz Skorski
Journal:  DNA Repair (Amst)       Date:  2005-11-16

5.  Chromosomal translocation mechanisms at intronic alu elements in mammalian cells.

Authors:  Beth Elliott; Christine Richardson; Maria Jasin
Journal:  Mol Cell       Date:  2005-03-18       Impact factor: 17.970

6.  Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression.

Authors:  Ulrike Bacher; Torsten Haferlach; Wolfgang Hiddemann; Susanne Schnittger; Wolfgang Kern; Claudia Schoch
Journal:  Cancer Genet Cytogenet       Date:  2005-02

7.  Genetic steps of mammalian homologous repair with distinct mutagenic consequences.

Authors:  Jeremy M Stark; Andrew J Pierce; Jin Oh; Albert Pastink; Maria Jasin
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

8.  BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.

Authors:  Michal O Nowicki; Rafal Falinski; Mateusz Koptyra; Artur Slupianek; Tomasz Stoklosa; Ewa Gloc; Margaret Nieborowska-Skorska; Janusz Blasiak; Tomasz Skorski
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

9.  BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

Authors:  Mateusz Koptyra; Rafal Falinski; Michal O Nowicki; Tomasz Stoklosa; Ireneusz Majsterek; Margaret Nieborowska-Skorska; Janusz Blasiak; Tomasz Skorski
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113

10.  Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

Authors:  Mhairi Copland; Ashley Hamilton; Lucy J Elrick; Janet W Baird; Elaine K Allan; Niove Jordanides; Martin Barow; Joanne C Mountford; Tessa L Holyoake
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

View more
  39 in total

1.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

2.  Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.

Authors:  Tariq I Mughal; Jerald P Radich; Richard A Van Etten; Alfonso Quintás-Cardama; Tomasz Skorski; Farhad Ravandi; Daniel J DeAngelo; Carlo Gambacorti-Passerini; Giovanni Martinelli; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2011-09       Impact factor: 10.047

3.  Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.

Authors:  Jee Hyun Kong; Yeung-Chul Mun; Seonwoo Kim; Hang Seok Choi; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Joon Ho Moon; Sang Kyun Sohn; Sung-Hyun Kim; Chul Won Jung; Dong Hwan Dennis Kim
Journal:  Int J Hematol       Date:  2012-07-21       Impact factor: 2.490

Review 4.  BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Authors:  B A Burke; M Carroll
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

Review 5.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

Review 6.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

7.  BCR/ABL stimulates WRN to promote survival and genomic instability.

Authors:  Artur Slupianek; Tomasz Poplawski; Stanislaw K Jozwiakowski; Kimberly Cramer; Dariusz Pytel; Ewelina Stoczynska; Michal O Nowicki; Janusz Blasiak; Tomasz Skorski
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

8.  Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Authors:  Artur Slupianek; Yashodhara Dasgupta; Shu-Yue Ren; Ewa Gurdek; Milene Donlin; Margaret Nieborowska-Skorska; Fabrice Fleury; Tomasz Skorski
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

Review 9.  Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

Authors:  Danilo Perrotti; Giovannino Silvestri; Lorenzo Stramucci; Justine Yu; Rossana Trotta
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

10.  BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.

Authors:  Margret S Fernandes; Mamatha M Reddy; Jeffrey R Gonneville; Scott C DeRoo; Klaus Podar; James D Griffin; David M Weinstock; Martin Sattler
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.